Page 10 - Nasdaq Alpn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq alpn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Alpn Today - Breaking & Trending Today

Alpine Immune Sciences, Inc. Forecasted to Earn Q1 2022 Earnings of ($0.27) Per Share (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Stock analysts at Wedbush issued their Q1 2022 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a research note issued to investors on Monday, March 21st. Wedbush analyst R. Driscoll anticipates that the biotechnology company will earn ($0.27) per share for the […] ....

Securities Exchange Commission , Crossover Management , Alpine Immune Sciences , Zacks Investment Research , Blackrock Inc , Alpine Immune Sciences Inc , Alpine Immune Sciences Get Rating , Frazier Management , Life Sciences Viiil Frazier , Get Rating , Immune Sciences , Investment Research , Life Sciences Viii , Exchange Commission , Nasdaq Alpn , Earnings Estimates ,

Alpine Immune Sciences (NASDAQ:ALPN) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the […] ....

United States , Allspring Global Investments Holdings , Securities Exchange Commission , Alpine Immune Sciences , Zacks Investment Research , Alpine Immune Sciences Inc , America Corp , Alpine Immune Sciences Get Rating , Life Sciences Viiil Frazier , Barclays Plc , Citigroup Inc , Get Rating , Immune Sciences , Immune Sciences Inc , Nivalis Therapeutics , Life Sciences Viii , Exchange Commission , Nasdaq Alpn ,

-$0.08 Earnings Per Share Expected for Alpine Immune Sciences, Inc. (NASDAQ:ALPN) This Quarter

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings. Alpine Immune Sciences posted earnings per share of ($0.45) in the same quarter last year, which would indicate a positive […] ....

Crossover Management , Alpine Immune Sciences , Zacks Investment Research , Blackrock Inc , Alpine Immune Sciences Inc , Alpine Immune Sciences Get Rating , Frazier Management , Life Sciences Viiil Frazier , Wall Street , Get Rating , Alpine Immune Science , Immune Sciences , Alpine Immune , Investment Research , Life Sciences Viii , Nasdaq Alpn ,

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.23 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23), MarketWatch Earnings reports. Alpine Immune Sciences had a negative return on equity of 58.85% and a negative net margin of 169.03%. Shares […] ....

Geode Capital Management , Alpine Immune Sciences , Zacks Investment Research , Alpine Immune Sciences Inc , Blackrock Inc , Earnings History For Alpine Immune Sciences , Alpine Immune Sciences Company Profile Get Rating , York Mellon Corp , Life Sciences Viiil Frazier , Dimensional Fund Advisors , Get Rating , Marketwatch Earnings , Immune Sciences , Life Sciences Viii , Street Corp , Capital Management , Fund Advisors , New York Mellon Corp , Investment Research , Immune Sciences Company Profile , Nasdaq Alpn ,